Angela Branche, Nadine Rouphael, David Diemert, Ann Falsey, Cecilia Losada, Lindsey R Baden, Sharon Frey, Jennifer Whitaker, Susan Little, Evan Anderson, Emmanuel Walter, Richard Novak, Richard Rupp, Lisa Jackson, Tara Babu, Angelica Kottkamp, Annie Luetkemeyer, Lilly Immergluck, Rachel Presti, Martin Backer, Patricia Winokur, Siham Mahgoub, Paul Goepfert, Dahlene Fusco, Elissa Malkin, Jeff Bethony, Edward Walsh, Daniel Graciaa, Hady Samaha, Amy Sherman, Stephen Walsh, Getahun Abate, Zacharoula Oikonomopoulou, Hana El Sahly, Thomas Martin, Satoshi Kamidani, Michael Smith, Benjamin Ladner, Laura Porterfield, Maya Dunstan, Anna Wald, Tamia Davis, Robert Atmar, Mark Mulligan, Kirsten Lyke, Christine Posavad, Megan Meagher, David Stephens, Kathleen Neuzil, Kuleni Abebe, Heather Hill, Jim Albert, Kalyani Telu, Jinjian Mu, Teri Lewis, Lisa Giebeig, Amanda Eaton, Antonia Netzl, Sam Wilks, Sina Tureli, Mamodikoe Makhene, Sonja Crandon, David Montefiori, Mat Makowski, Derek Smith, Seema Nayak, Paul Roberts, John Beigel
Vaccine protection against COVID-19 wanes over time and has been impacted by the emergence of new variants with increasing escape of neutralization. The COVID-19 Variant Immunologic Landscape (COVAIL) randomized clinical trial (clinicaltrials.gov NCT05289037) compares the breadth, magnitude and durability of antibody responses induced by a second COVID-19 vaccine boost with mRNA (Moderna mRNA-1273 and Pfizer-BioNTech BNT162b2), or adjuvanted recombinant protein (Sanofi CoV2 preS DTM-AS03) monovalent or bivalent vaccine candidates targeting ancestral and variant SARS-CoV-2 spike antigens (Beta, Delta and Omicron BA...
May 5, 2023: Research Square